Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival ...

We recently published 10 Stocks That Jim Cramer Talked About. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim ...

Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, ...

Eli Lilly said on Tuesday its drug for a type of blood cancer was more effective in a head-to-head study against AbbVie's ...

Eli Lilly’s Jaypirca (pirtobrutinib) has been shown to be superior to Johnson & Johnson (J&J) and AbbVie’s star Bruton's ...

Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral ...

Eli Lilly (LLY) stock in focus as its cancer drug Jaypirca hits main goal in a Phase 3 trial against Imbruvica of J&J (JNJ) ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic and Mounjaro, the pharmaceutical company says.

Eli Lilly is walking through the Gate, inking a deal worth up to $856 million with a biotech aiming to build out a new ...

Eli Lilly's acquisition of Vere Therapeutics promises to revolutionize cardiovascular care with innovative one-time gene ...

Eli Lilly and Company (NYSE:LLY) is one of the stocks in Jim Cramer’s spotlight. Answering a caller’s query about the company, Cramer said: “Alright, listen to me. This one is one that everyone’s ...

Eli Lilly is expected to release its fiscal second-quarter earnings next month, and analysts project a double-digit profit ...